Simone Fulda Selected Research

BI 6727

1/2019	A Perspective on Polo-Like Kinase-1 Inhibition for the Treatment of Rhabdomyosarcomas.
8/2017	Eribulin alone or in combination with the PLK1 inhibitor BI 6727 triggers intrinsic apoptosis in Ewing sarcoma cell lines.
1/2016	Synergistic induction of apoptosis by a polo-like kinase 1 inhibitor and microtubule-interfering drugs in Ewing sarcoma cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Simone Fulda Research Topics

Disease

153	Neoplasms (Cancer) 01/2021 - 04/2002
22	Rhabdomyosarcoma 10/2020 - 09/2008
22	Neuroblastoma 01/2020 - 04/2002
19	Glioblastoma (Glioblastoma Multiforme) 11/2021 - 08/2002
13	Pancreatic Neoplasms (Pancreatic Cancer) 01/2016 - 11/2005
12	Leukemia 09/2017 - 04/2003
11	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2020 - 02/2009
8	Glioma (Gliomas) 11/2021 - 08/2002
8	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020 - 08/2007
6	Carcinoma (Carcinomatosis) 01/2021 - 11/2002
6	Sarcoma (Soft Tissue Sarcoma) 10/2020 - 01/2012
6	Ewing Sarcoma (Sarcoma, Ewing) 01/2020 - 04/2002
6	Lymphoma (Lymphomas) 01/2016 - 04/2003
5	Hepatocellular Carcinoma (Hepatoma) 08/2020 - 02/2011
4	Inflammation (Inflammations) 01/2021 - 01/2017
4	Carcinogenesis 01/2018 - 02/2009
4	Hypoxia (Hypoxemia) 04/2016 - 04/2007
4	Necrosis 03/2011 - 05/2009
3	Hematologic Neoplasms (Hematological Malignancy) 01/2014 - 08/2007
2	Starvation 01/2021 - 04/2016
2	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2020 - 03/2008
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2020 - 12/2015
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2020 - 01/2020
2	Breast Neoplasms (Breast Cancer) 01/2019 - 09/2014
2	Reperfusion Injury 01/2019 - 01/2017
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2018 - 01/2017
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 11/2017 - 10/2017
2	Lung Neoplasms (Lung Cancer) 11/2017 - 01/2013
2	Genomic Instability 07/2017 - 01/2016

Drug/Important Bio-Agent (IBA)

46	Proteins (Proteins, Gene)FDA Link 01/2021 - 10/2006
26	Pharmaceutical PreparationsIBA 01/2019 - 08/2002
18	LigandsIBA 01/2020 - 04/2002
18	CaspasesIBA 10/2018 - 04/2002
14	Death Domain ReceptorsIBA 01/2016 - 04/2002
12	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2017 - 04/2002
11	Inhibitor of Apoptosis ProteinsIBA 01/2020 - 01/2004
9	Phosphotransferases (Kinase)IBA 11/2021 - 08/2007
9	Histone Deacetylase InhibitorsIBA 01/2020 - 10/2005
8	ResveratrolIBA 10/2012 - 01/2004
7	Reactive Oxygen Species (Oxygen Radicals)IBA 11/2021 - 04/2016
7	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2018 - 08/2008
7	NF-kappa B (NF-kB)IBA 06/2015 - 06/2003
7	Betulinic AcidIBA 01/2014 - 10/2004
6	Sorafenib (BAY 43-9006)FDA Link 01/2019 - 10/2016
6	Transcription Factors (Transcription Factor)IBA 01/2019 - 04/2007
6	CytokinesIBA 09/2017 - 02/2011
5	Biological ProductsIBA 01/2021 - 06/2003
5	Bortezomib (Velcade)FDA Link 10/2017 - 09/2010
5	Caspase 8 (Caspase-8)IBA 01/2017 - 04/2002
4	Biomarkers (Surrogate Marker)IBA 01/2021 - 10/2013
4	Proteasome InhibitorsIBA 01/2020 - 05/2011
4	Vincristine (Oncovin)FDA LinkGeneric 01/2019 - 08/2015
4	InterferonsIBA 01/2019 - 12/2014
4	2- (1H- indazol- 4- yl)- 6- (4- methanesulfonylpiperazin- 1- ylmethyl)- 4- morpholin- 4- ylthieno(3,2- d)pyrimidineIBA 01/2018 - 01/2012
4	Etoposide (VP 16)FDA LinkGeneric 01/2018 - 11/2014
4	Temozolomide (Temodar)FDA LinkGeneric 11/2016 - 01/2014
4	TOR Serine-Threonine KinasesIBA 04/2015 - 01/2007
4	PI103IBA 04/2015 - 05/2011
3	Loperamide (Imodium)FDA LinkGeneric 11/2021 - 01/2018
3	bafilomycin A1IBA 01/2021 - 06/2013
3	venetoclaxIBA 10/2020 - 01/2018
3	Histone Deacetylases (Histone Deacetylase)IBA 01/2020 - 07/2012
3	AntioxidantsIBA 01/2020 - 10/2015
3	Lysine (L-Lysine)FDA Link 01/2020 - 01/2017
3	GANT 61IBA 11/2019 - 04/2015
3	Oleanolic AcidIBA 01/2019 - 08/2015
3	BI 6727IBA 01/2019 - 01/2016
3	Cisplatin (Platino)FDA LinkGeneric 01/2018 - 02/2011
3	Small Interfering RNA (siRNA)IBA 01/2018 - 03/2008
3	Polo-Like Kinase 1IBA 02/2016 - 08/2015
3	Antineoplastic Agents (Antineoplastics)IBA 01/2016 - 08/2012
3	Caspase 3 (Caspase-3)IBA 09/2015 - 03/2009
3	DNA (Deoxyribonucleic Acid)IBA 09/2015 - 10/2009
3	TNF-Related Apoptosis-Inducing LigandIBA 05/2015 - 03/2008
3	dactolisibIBA 04/2015 - 01/2013
3	Chloroquine (Aralen)FDA LinkGeneric 04/2015 - 01/2013
2	Cathepsin BIBA 11/2021 - 01/2014
2	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 11/2021 - 01/2021
2	Pimozide (Orap)FDA Link 11/2021 - 01/2018
2	Sirolimus (Rapamycin)FDA Link 11/2021 - 02/2015
2	Messenger RNA (mRNA)IBA 02/2021 - 01/2018
2	Type I Tumor Necrosis Factor ReceptorsIBA 01/2021 - 01/2020
2	Amino Acids FDA Link 01/2021 - 04/2016
2	S63845IBA 10/2020 - 01/2020
2	AlpelisibIBA 01/2020 - 01/2018
2	Dexamethasone (Maxidex)FDA LinkGeneric 03/2018 - 07/2014
2	gossypol acetic acidIBA 01/2018 - 01/2017
2	eribulin FDA Link 08/2017 - 08/2015
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 07/2017 - 12/2015
2	benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketoneIBA 01/2017 - 01/2017
2	Glutathione (Reduced Glutathione)IBA 09/2016 - 10/2015
2	Glucose (Dextrose)FDA LinkGeneric 04/2016 - 07/2010
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2016 - 10/2013
2	SurvivinIBA 09/2015 - 01/2004

Therapy/Procedure

91	Therapeutics 10/2020 - 04/2002
28	Drug Therapy (Chemotherapy) 01/2019 - 04/2002
12	Immunotherapy 01/2013 - 04/2003
7	Radiotherapy 01/2021 - 09/2008
4	Molecular Targeted Therapy 01/2011 - 05/2008
3	Ligation 01/2004 - 08/2002